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The results of the Magpie Trial, a double-blind randomised
controlled trial to assess the role of magnesium sulphate
(MgSO4) in preventing eclampsia in women with pre-
eclampsia, were published recently.1 Several South African
units were among the 175 hospitals from 33 participating
countries. In total, 2 678 of the 10 123 women recruited came
from this country. The incidence of eclampsia in the study was
1.9% in the placebo group, compared with 0.8% among women
randomised to receive MgSO4. Risk reduction represents a risk
reduction of 59%. Put differently, it means that 1 case of
eclampsia will be prevented for every 91 women with pre-
eclampsia given MgSO4. Risk reduction was influenced by the
severity of pre-eclampsia at presentation. The number of
patients needed to treat to prevent 1 case of eclampsia was 63
and 109 in those women with severe and non-severe pre-
eclampsia respectively. Of the more than 10 000 women, 26%
had severe pre-eclampsia and 16% had imminent eclampsia.
Only 41% of women in the MgSO4 group who convulsed had
their seizure while receiving trial medication. The comparable
figure for the placebo group was 56%.
The maternal mortality rate was 316/100 000. Of the 31
maternal deaths, 11 occurred in women randomised to receive
MgSO4. Although this reduction of 48% was not statistically
significant, it may represent a true difference. It is of interest
that of the mothers who died, only 1 (2.6%) in the MgSO4
group and 3 (3.2%) in the placebo group had eclampsia.
Clearly, the reduction in maternal deaths is not a direct result
of the prevention of eclampsia. It may be that MgSO4 has some
protective  effect on endothelial cell function, which extends
beyond its ability to decrease convulsions. In the Collaborative
Eclampsia Trial,2 there were also trends towards fewer deaths
among mothers who received MgSO4 rather than either
diazepam or phenytoin.2
There were some other interesting findings in the Magpie
study. There were significantly fewer side-effects in the placebo
group (23% v. 4%), while significantly more mothers in the
MgSO4 group requested that treatment be stopped early (5% v.
2%). Furthermore, side-effects were significantly fewer in
women who received their MgSO4 by the intravenous instead
of the intramuscular route (20.3% v. 26.7%).
There was a significant reduction in abruptio placentae in the
MgSO4 group (1.4% v. 2.6%). However, there were no other
benefits for the baby in terms of Apgar scores, perinatal
mortality or admission to neonatal intensive care unit (ICU). It
is difficult to explain this in terms of the improved maternal
outcome. Clearly the follow-up study of babies born in this
trial is of utmost importance.
What are the clinical implications of these results? The
African co-workers met during the collaborators meeting in
Oxford and prepared a consensus statement. It is agreed that
MgSO4 for women with pre-eclampsia reduces the risk of
eclampsia, which is small. The use of MgSO4 in specific settings
will depend on the capacity to administer it safely, taking into
account the site-specific costs and benefits. MgSO4 should be
available at all facilities providing services for pregnant
women, and health workers should be trained and permitted
to administer it. Strategies to identify women with pre-
eclampsia and facilities to transfer women to the appropriate
level of care must be improved.
The indications for the use of MgSO4 are not so obvious. It
was previously clearly shown that eclampsia is an absolute
indication for MgSO4.
2 One would probably now add moderate
to severe pre-eclampsia as relative indications at the time of
delivery and during transport of the patient to a more
appropriate level of care. At tertiary level, its administration
should also be considered during assessment of women with
pre-eclampsia for possible expectant management. The initial
dose of MgSO4 is safe, but maintenance doses should only be
given when facilities for adequate monitoring of the mother are
available. The Magpie study only provides safety data for
treatment duration of 24 hours and longer treatment should be
undertaken with caution. A loading dose of 4 g should be
given by intravenous infusion over 20 minutes. The
maintenance doses are 1 g per hour if given by intravenous
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The South African Magpie Trial Collaborators Group is made up
of South African specialists interested in women’s health. All are
well known in the field of hypertension in pregnancy and perinatal
problems in resource-constrained settings. They are
D W Steyn (Tygerberg Hospital); G J Hofmeyr (Cecilia Makiwane
and Frere Hospitals); K C Jackson, AKambaran (Mankweng
Hospital); P MacDonald (Pretoria Academic Hospital); L Matsela
(Medunsa); J Moodley (King Edward VIII Hospital); R C
Pattinson (Kalafong Hospital); N E Pirani (Chris Hani
Baragwanath Hospital); M G Schoon (Pelonomi Hospital).
There is an increasing amount of collaborative and contract
research taking place, with the South African arm constituting
one of several international country sites.  Of necessity the
outcome measures are standardised, and the majority of these
outcome measures are developed in Europe or North America
and then translated for use in other language and cultural
groups. 
An outcome measure of importance that is often
incorporated into research is HRQoL, which can encompass
physical and emotional health, functional ability and life
satisfaction. The EQ-5D is a generic single index measure that
is widely used to measure HRQoL. 1, 2 It is a short questionnaire,
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infusion or 5 g every 4 hours by intramuscular injection.
Maintenance doses should only be given provided that urine
output, reflexes and respiration rate are all satisfactory. The
preferred way of administration is by intravenous infusion if
monitoring of the drip can be done adequately, otherwise by
intramuscular injection.
The definitions used in the study for moderate and severe
pre-eclampsia are very cumbersome for the clinician. At the
collaborators meeting it was suggested that a reasonable
working definition of moderate to severe pre-eclampsia be
defined as a diastolic blood pressure ‡ 110 mmHg once, or 
‡ 100 mmHg persisting after rest, plus proteinuria ‡ 2+ or
pre-eclampsia with evidence of organ damage (low platelets,
rising liver enzymes, deteriorating renal function) or symptoms
of severe pre-eclampsia.
Eclampsia is a rare and not entirely preventable condition.
The appropriate use of MgSO4 may contribute to improved
maternal outcome in women with moderate to severe pre-
eclampsia, but the long-term effects on babies need to be
investigated further.
1. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies,
benefit from magnesium sulphate?The Magpie Trial: a randomised placebo-controlled trial.
Lancet 2002; 359: 1877-1890.
2. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia?
Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455-1463.
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The pitfalls of translation — a case study based on the
translation of the EQ-5D into Xhosa
Siviwe Mkoka, Jonathan Vaughan, Tarryn Wylie, Heather Yelland, Jennifer Jelsma
Mr Mkoka and Dr Jelsma are employed in the School of Health
and Rehabilitation Sciences of the University of Cape Town as a
junior and senior lecturer respectively. The other authors are
physiotherapists in clinical practice.
There is an evident need for standardised, internationally
recognised instruments to measure health-related outcomes
that are also locally applicable. The European Quality of Life
5-Dimensions (EQ-5D) is a widely used measure of health-
related quality of life (HRQoL) that was translated into
Xhosa. This communication outlines some of the different
cultural and linguistic issues that had to be addressed during
the translation process.
The translation guidelines provided by the EuroQol group
were followed. This involved both forward and backward
translations by Xhosa speakers, with consensus meetings
after each. Thereafter, lay panel respondent testing of the
consensus version was performed.    
Eventually a credible Xhosa version of the EQ-5D was
produced. Concepts which proved surprisingly difficult to
transfer across the languages and cultures included
‘mobility’, ‘confined to bed’ and the choice of word to denote
‘male’.
The translation process prompted lengthy discussion and
proved more challenging than initially anticipated.  Despite
the rigorous process followed, later additions had to be made
to the questionnaire after field testing. It would appear that
extreme caution should be exercised when using a
questionnaire in a culture and language different from the
one in which it was originally developed and validated. If
this is not done, the validity of cross-cultural research projects
may be open to question.
